GO Capital Fund

Rimsys is a leading provider of Regulatory Information Management (RIM) software tailored for medical technology companies. Designed by regulatory affairs professionals, Rimsys offers a cloud-based solution that digitizes and automates compliance processes to ensure adherence to evolving global regulations. This comprehensive software simplifies the management of global Unique Device Identification (UDI) requirements and supports various aspects of regulatory affairs, including product registration, standards management, and regulatory intelligence. By enabling medical device companies to efficiently track product registrations and monitor relevant standards, Rimsys transforms regulatory compliance into a more organized and manageable process for teams and their international partners.

LeddarTech Inc. specializes in advanced detection and ranging systems using time-of-flight measurement technology with infrared LEDs. The company offers a range of smart sensor modules, including single-element and multi-element systems tailored for various applications, such as industrial, traffic management, and smart home solutions. LeddarTech's technology is particularly focused on enhancing advanced driver assistance systems (ADAS) and autonomous driving by providing perception solutions that integrate data from various sensor types, including cameras and radar. Their flagship platform, LeddarVision™, facilitates the creation of comprehensive 3D environmental models, addressing critical challenges in environmental sensing and perception. With over 140 patents granted or pending, LeddarTech is committed to innovation in the automotive sector, serving original equipment manufacturers (OEMs) and automotive suppliers to accelerate development cycles and improve time-to-market. Founded in 2007 and based in Quebec City, Canada, the company also maintains a research and development office in Toronto.

WhatsNexx Moments leverages the world’s leading marketing applications, consolidating campaign management across channels and locations to build intuitive and delightful customer experiences. Our suite and solutions empower marketers to collect and integrate raw customer data into profiles and segments, to design and manage sophisticated, automated campaigns, and to visualize and optimize the customer journey in real-time - all using the tools and apps you already trust to deliver the front line experiences.

Alethia BioTherapeutics, Inc. is a biotechnology company based in Montreal, Canada, specializing in the discovery and development of monoclonal antibody-based therapeutics. The company focuses on critical areas such as cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and cancer-induced bone loss. Its product portfolio includes Isogranulatimide, a G2 checkpoint inhibitor that enhances the efficacy of various DNA-damaging chemotherapeutic agents, and sCLU, a glycoprotein linked to several malignancies, including prostate and breast cancers. Additionally, Alethia BioTherapeutics offers AB-0447, which targets a specific antigen prevalent in over eighty-five percent of ovarian cancer cases, and AB-0440, a protein that plays a role in osteoclast differentiation. Established in 2002, the company employs patented STAR discovery technology to develop therapeutics aimed at invasive carcinomas and associated complications.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on developing and commercializing etripamil for various cardiovascular conditions. Etripamil is a novel short-acting calcium channel blocker designed to be administered as a rapid-onset nasal spray, specifically targeting the termination of episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently conducting Phase III clinical trials for etripamil in the treatment of PSVT and is also exploring its potential applications for atrial fibrillation, angina, and other related cardiovascular disorders. Founded in 2003, Milestone Pharmaceuticals aims to address unmet medical needs in cardiovascular disease management through innovative therapeutic solutions.

WhatsNexx Moments leverages the world’s leading marketing applications, consolidating campaign management across channels and locations to build intuitive and delightful customer experiences. Our suite and solutions empower marketers to collect and integrate raw customer data into profiles and segments, to design and manage sophisticated, automated campaigns, and to visualize and optimize the customer journey in real-time - all using the tools and apps you already trust to deliver the front line experiences.

Neuralitic Systems specializes in mobile data intelligence technology, assisting mobile service operators in analyzing user behaviors that impact data service adoption. By identifying and understanding emerging trends, the company enables its clients to enhance decision-making processes related to subscriber acquisition, conversion, and retention. This approach helps operators dynamically adapt to user habits, ultimately fostering revenue growth from data services.

Alethia BioTherapeutics, Inc. is a biotechnology company based in Montreal, Canada, specializing in the discovery and development of monoclonal antibody-based therapeutics. The company focuses on critical areas such as cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and cancer-induced bone loss. Its product portfolio includes Isogranulatimide, a G2 checkpoint inhibitor that enhances the efficacy of various DNA-damaging chemotherapeutic agents, and sCLU, a glycoprotein linked to several malignancies, including prostate and breast cancers. Additionally, Alethia BioTherapeutics offers AB-0447, which targets a specific antigen prevalent in over eighty-five percent of ovarian cancer cases, and AB-0440, a protein that plays a role in osteoclast differentiation. Established in 2002, the company employs patented STAR discovery technology to develop therapeutics aimed at invasive carcinomas and associated complications.

Leap Medical, Inc. engages in designing, developing, manufacturing, and marketing products that provide the earliest possible indicators of a patient's medical condition. The company is based in Montreal, Canada.

Allostera Pharma is a preclinical-stage biopharmaceutical company focused on autoimmune diseases such as psoriatic arthritis, gout and type II diabetes.

Neuralitic Systems specializes in mobile data intelligence technology, assisting mobile service operators in analyzing user behaviors that impact data service adoption. By identifying and understanding emerging trends, the company enables its clients to enhance decision-making processes related to subscriber acquisition, conversion, and retention. This approach helps operators dynamically adapt to user habits, ultimately fostering revenue growth from data services.

Alethia BioTherapeutics, Inc. is a biotechnology company based in Montreal, Canada, specializing in the discovery and development of monoclonal antibody-based therapeutics. The company focuses on critical areas such as cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and cancer-induced bone loss. Its product portfolio includes Isogranulatimide, a G2 checkpoint inhibitor that enhances the efficacy of various DNA-damaging chemotherapeutic agents, and sCLU, a glycoprotein linked to several malignancies, including prostate and breast cancers. Additionally, Alethia BioTherapeutics offers AB-0447, which targets a specific antigen prevalent in over eighty-five percent of ovarian cancer cases, and AB-0440, a protein that plays a role in osteoclast differentiation. Established in 2002, the company employs patented STAR discovery technology to develop therapeutics aimed at invasive carcinomas and associated complications.